# reload+after+2024-01-22 18:43:29.935835
address1§350 Collins Street
address2§Level 14
city§Melbourne
state§VIC
zip§3000
country§Australia
phone§61 3 9349 4906
website§https://alteritytherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
fullTimeEmployees§11
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Geoffrey Paul Kempler B.Sc.', 'age': 68, 'title': 'Co-Founder & Non-Executive Chairman', 'yearBorn': 1955, 'fiscalYear': 2023, 'totalPay': 210600, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. David A. Stamler M.D.', 'age': 62, 'title': 'Chief Executive Officer', 'yearBorn': 1961, 'fiscalYear': 2023, 'totalPay': 622424, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Kathryn J. E. Andrews B.Com, CPA', 'age': 56, 'title': 'Chief Financial Officer', 'yearBorn': 1967, 'fiscalYear': 2023, 'totalPay': 220097, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Rudolph Emile Tanzi Ph.D.', 'age': 64, 'title': 'Chief Scientific Advisor and Member of Research & Development Advisory Board', 'yearBorn': 1959, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Steven D. Targum', 'title': 'Chief Medical Advisor', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Robert  Cherny', 'title': 'Head of Research', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A.', 'age': 64, 'title': 'Company Secretary', 'yearBorn': 1959, 'fiscalYear': 2023, 'totalPay': 67220, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.825
priceToSalesTrailing12Months§2.2220557
currency§USD
dateShortInterest§1702598400
exchange§NCM
quoteType§EQUITY
shortName§Alterity Therapeutics Limited
longName§Alterity Therapeutics Limited
firstTradeDateEpochUtc§1064842200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§7d2b4277-cadd-3872-afb9-8272c07044dd
gmtOffSetMilliseconds§-18000000
targetHighPrice§10.0
targetLowPrice§10.0
targetMeanPrice§10.0
targetMedianPrice§10.0
recommendationMean§1.0
recommendationKey§strong_buy
numberOfAnalystOpinions§1
quickRatio§5.577
grossMargins§0.92721003
ebitdaMargins§0.0
trailingPegRatio§None
